Earnings call transcript: Radico Khaitan beats Q2 2026 estimates, stock slips

Radico Khaitan posted record Q2 FY2027 results, with revenue of ₹1,746 crore up 7% year on year, EBITDA of ₹356 crore and a 20.4% margin, up 462 basis points. EPS of 17.25 beat the 16.36 forecast by 5.44%, while Prestige & Above volumes grew 36%; management raised FY2027 Prestige & Above growth guidance to 30% and maintained its roughly 20% EBITDA margin target. Shares nevertheless fell 3.26% to ₹4,150, amid sequential gross-margin compression of 109 basis points and volatility in grain, packaging and freight costs.

Analysis

The key question is whether premium mix can keep converting into cash, not whether Radico Khaitan can post another headline beat. The 36% Prestige & Above volume increase against 7% total volume growth signals a faster-growing, higher-value portfolio, but also leaves results increasingly sensitive to continued premium demand and execution in vodka. If that growth moderates, regular-category volumes are not positioned to provide much of a buffer.

Near term, gross-margin sequential compression and the roughly ₹27 crore combined raw-material/packaging impact make the 20% full-year EBITDA-margin goal dependent on cost stabilization and mix, rather than a clean, broad-based margin expansion. Management’s expected grain relief from the new crop season is a hypothesis to verify; packaging and freight exposure may not normalize on the same timetable. State-level price revisions could help, but regulatory timing creates a pass-through lag. Higher inventory adds a separate test: whether the planned second-half working-capital normalization appears in cash conversion, not just earnings.

Over 1–3 months, monitor gross margin, inventory/receivables and operating cash flow alongside state price approvals. Over 6–18 months, the structural upside is premiumization and vodka-category expansion; the counter-risk is competitive entry eroding price/mix economics. The share-price decline despite a beat is consistent with expectations and valuation risk, but does not itself establish a broken thesis. With no supplied company identity/ticker mapping or valuation inputs, avoid a price-specific or relative-value call.

Key Decisions for Investors

• Do not chase the post-results dip on the earnings beat alone. Treat Radico Khaitan as a watch/add-on-confirmation rather than an immediate momentum buy; require evidence that gross margin stabilizes and second-half cash conversion improves.
• Set a 1–3 month alert for gross-margin trend, working-capital normalization and operating cash flow. If inventory remains elevated or cash conversion weakens while margin pressure persists, reduce exposure: that would challenge the quality of the reported growth.
• Reassess the margin thesis if the approximately 20% FY27 EBITDA-margin outlook is cut, or if grain and packaging costs fail to ease while state price revisions are delayed. Conversely, stable margins with lower working capital would strengthen the case for the premiumization thesis.
• No pair trade is recommended without comparable valuation, category-mix and cost-exposure data for competitors; verify those inputs before expressing a relative-value view.